Cargando…
Advances in the management of pulmonary arterial hypertension
The management of pulmonary arterial hypertension (PAH) has significantly evolved over the last decades in the wake of more sensitive diagnostics and specialized clinical programs that can provide focused medical care. In the current era of PAH care, 1-year survival rates have increased to 86%–90% f...
Autores principales: | Deshwal, Himanshu, Weinstein, Tatiana, Sulica, Roxana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8485135/ https://www.ncbi.nlm.nih.gov/pubmed/34580123 http://dx.doi.org/10.1136/jim-2021-002027 |
Ejemplares similares
-
Long-term impact of add-on sequential triple combination therapy in pulmonary arterial hypertension: real world experience
por: Deshwal, Himanshu, et al.
Publicado: (2023) -
Early Observations on the Use of Riociguat in a Large, Metropolitan Pulmonary Arterial Hypertension/Chronic Thromboembolic Pulmonary Hypertension Treatment Center
por: Sulica, Roxana, et al.
Publicado: (2015) -
Pulmonary Hypertension Due to Common Respiratory Conditions: Classification, Evaluation and Management Strategies
por: Fein, Daniel G., et al.
Publicado: (2016) -
Clinical and hemodynamic benefit of macitentan and riociguat upfront combination in patients with pulmonary arterial hypertension
por: Sulica, Roxana, et al.
Publicado: (2019) -
COVID-19 in Pulmonary Artery Hypertension (PAH) Patients: Observations from a Large PAH Center in New York City
por: Sulica, Roxana, et al.
Publicado: (2021)